BRIDGEWAY CAPITAL MANAGEMENT, LLC - CONATUS PHARMACEUTICALS INC ownership

CONATUS PHARMACEUTICALS INC's ticker is CNAT and the CUSIP is 20600T108. A total of 33 filers reported holding CONATUS PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BRIDGEWAY CAPITAL MANAGEMENT, LLC ownership history of CONATUS PHARMACEUTICALS INC
ValueSharesWeighting
Q4 2019$8,000
-69.2%
19,500
-76.6%
0.00%
Q3 2019$26,000
+18.2%
83,3000.0%0.00%
Q2 2019$22,000
-88.9%
83,300
-54.6%
0.00%
-100.0%
Q1 2019$198,000
+10.6%
183,300
+77.4%
0.00%0.0%
Q4 2018$179,000
-77.4%
103,300
-24.2%
0.00%
-75.0%
Q3 2018$791,000
+35.7%
136,3000.0%0.01%
+33.3%
Q2 2018$583,000
-27.1%
136,3000.0%0.01%
-33.3%
Q1 2018$800,000
+27.0%
136,3000.0%0.01%
+28.6%
Q4 2017$630,000
-15.8%
136,3000.0%0.01%
-22.2%
Q3 2017$748,000
-2.0%
136,300
+2.9%
0.01%0.0%
Q2 2017$763,000
+17.6%
132,500
+17.8%
0.01%
+12.5%
Q1 2017$649,000
+9.4%
112,5000.0%0.01%0.0%
Q4 2016$593,000
+163.6%
112,5000.0%0.01%
+166.7%
Q3 2016$225,000
-3.0%
112,5000.0%0.00%
-25.0%
Q2 2016$232,000
-38.9%
112,500
-36.6%
0.00%
-33.3%
Q1 2016$380,000
+35.2%
177,500
+82.1%
0.01%
+20.0%
Q4 2015$281,000
-15.4%
97,500
+30.9%
0.01%
-28.6%
Q3 2015$332,000
-13.5%
74,5000.0%0.01%
-12.5%
Q2 2015$384,000
-28.1%
74,500
-0.7%
0.01%
-27.3%
Q1 2015$534,000
-19.7%
75,000
-21.1%
0.01%
-26.7%
Q4 2014$665,000
+14.5%
95,0000.0%0.02%0.0%
Q3 2014$581,000
+154.8%
95,000
+280.0%
0.02%
+150.0%
Q2 2014$228,000
+39.9%
25,000
+25.0%
0.01%
+20.0%
Q1 2014$163,00020,0000.01%
Other shareholders
CONATUS PHARMACEUTICALS INC shareholders Q1 2020
NameSharesValueWeighting ↓
JBF Capital, Inc. 520,553$161,0000.03%
Kalos Management, Inc. 43,940$13,0000.01%
ACADIAN ASSET MANAGEMENT LLC 1,351,000$419,0000.00%
Quilter Plc 60,546$19,0000.00%
ALBION FINANCIAL GROUP /UT 12,000$4,0000.00%
REILLY FINANCIAL ADVISORS, LLC 22,011$7,0000.00%
MORGAN STANLEY 1,900$1,0000.00%
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 24,900$8,0000.00%
BlackRock Inc. 645,611$200,0000.00%
Bank of New York Mellon Corp 137,500$43,0000.00%
View complete list of CONATUS PHARMACEUTICALS INC shareholders